# Orbus Therapeutics, Inc.

> Orbus Therapeutics is a small, private, late-stage biopharmaceutical company developing oral eflornithine with lomustine for recurrent IDH-mutant grade 3 astrocytoma. Its Phase 3 STELLAR trial missed the primary overall-survival endpoint across all 343 participants, but a prospectively defined molecular subgroup aligned to the newer WHO tumor classification showed longer median overall and progression-free survival. The company now sits in the difficult space between an informative subgroup result and the regulatory, clinical, and commercial work required to turn it into a treatment option.

- **Founded:** 2012
- **Headquarters:** Palo Alto, United States
- **Founders:** Bob Myers (Co-founder; former CEO and president), Jason Levin (Co-founder; CEO, director and president)
- **Team size:** Approximately 3 employees in the supplied company data; the public leadership page also lists specialist executives and consultants.
- **Products:** Eflornithine oral solution, STELLAR Phase 3 program
- **Notable:** Raised $71 million across its expanded Series A financing., Secured FDA orphan-drug designation for eflornithine in anaplastic glioma and EU orphan medicinal product designation for glioma., Received FDA Breakthrough Therapy designation for eflornithine in anaplastic glioma in 2014.

## Products & services

- **Eflornithine oral solution** — Investigational oral formulation of the ornithine decarboxylase inhibitor eflornithine, studied with lomustine for recurrent IDH-mutant grade 3 astrocytoma.
- **STELLAR Phase 3 program** — A randomized, open-label, 343-patient study comparing eflornithine plus lomustine with lomustine alone after recurrence following radiation and temozolomide.

## Achievements

- Raised $71 million across its expanded Series A financing.
- Secured FDA orphan-drug designation for eflornithine in anaplastic glioma and EU orphan medicinal product designation for glioma.
- Received FDA Breakthrough Therapy designation for eflornithine in anaplastic glioma in 2014.
- Completed enrollment of 343 patients in the international Phase 3 STELLAR study.
- Reported median overall survival of 34.9 months versus 23.5 months in the IDH-mutant grade 3 subgroup, while the overall study population did not meet its primary endpoint.
- Obtained U.S. patent protection covering an oral eflornithine solution formulation and continued filing method-of-use patent applications.

## Latest updates

- **2024-11** — Orbus presented STELLAR subgroup results at the Society for Neuro-Oncology annual meeting: the intention-to-treat primary endpoint was not significant, while the recurrent IDH-mutant grade 3 subgroup showed longer median OS and PFS.
- **2025-02** — A U.S. patent application covering eflornithine compositions and methods for cancers including gliomas was published.
- **2025-03** — Co-founder Jason Levin moved from COO to president as co-founder Bob Myers stepped back from day-to-day leadership.
- **2025-12** — The peer-reviewed STELLAR paper was published online in the Journal of Clinical Oncology; the print issue followed in March 2026.

## Links

- Website: https://orbustherapeutics.com
- LinkedIn: http://www.linkedin.com/company/orbus-therapeutics-inc

---

Profile page: https://yespress.io/orbus-therapeutics-inc
Published by YesPress — https://yespress.io
Last updated: 2026-08-22